¼¼°èÀÇ DNA Á¦Á¶ ½ÃÀå : DNA À¯Çüº°, ¿ëµµº°, ±â¼úº°, µî±Þº°, »ý»ê ½ºÄÉÀϺ°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°
DNA Manufacturing Market, By Type of DNA, By Application, By Technology, By Grade, By Production Scale, By End User, By Geography
»óǰÄÚµå : 1812427
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,376,000
Unprintable PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,919,000
PDF & Excel (Multi User License - Up to 7 Users) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ÃÖ´ë 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â ÆÄÀÏÀÇ ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,171,000
PDF & Excel (Corporate User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ DNA Á¦Á¶ ½ÃÀåÀº 2025³â 64¾ï 4,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ°í, 2023³â±îÁö 195¾ï 6,000¸¸ ´Þ·¯¿¡ À̸¦ Àü¸ÁÀ¸·Î, 2025³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ ¼ºÀå·ü(CAGR) 17.2%·Î ¼ºÀåÀÌ ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁØ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 64¾ï 4,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2020-2024³â
¿¹Ãø±â°£ : 2025-2032³â CAGR : 17.20% 2032³â °¡Ä¡ ¿¹Ãø 195¾ï 6,000¸¸ ´Þ·¯

¼¼°èÀÇ DNA Á¦Á¶ ½ÃÀåÀº ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö »ê¾÷¿¡¼­ ºü¸£°Ô ¹ßÀüÇϰí ÀÖ´Â ºÐ¾ß·Î, Á¦¾à, ¿¬±¸, Áø´Ü, Ä¡·áÀÇ °¢ ¿µ¿ª¿¡¼­ ´Ù¾çÇÑ ¿ëµµ¸¦ À§ÇÑ µ¥¿Á½Ã¸®º¸ ÇÙ»ê(DNA)ÀÇ »ý»ê, ÇÕ¼º, »ó¾÷Àû Á¦Á¶¸¦ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº À¯Àü °øÇÐ, ÇÕ¼º »ý¹°ÇÐ ¹× ¸ÂÃãÇü ÀÇ·áÀÇ Àü·Ê¾ø´Â Áøº¸·Î Çö´ë ¹ÙÀÌ¿À °æÁ¦ÀÇ Áß¿äÇÑ ±¸¼º ¿ä¼Ò·Î ºÎ»óÇß½À´Ï´Ù. DNA Á¦Á¶¿¡´Â °íǰÁú DNA ±¸Á¶¹°, Çö󽺹̵å, ¿Ã¸®°í´ºÅ¬·¹¿ÀƼµå, ÇÕ¼º À¯ÀüÀÚ¸¦ ¸¸µå´Â È­ÇÐ ÇÕ¼º, È¿¼Ò »ý»ê, ¹ÙÀÌ¿À Á¦Á¶ ±â¼ú µîÀÇ °í±Þ °øÁ¤ÀÌ Æ÷ÇԵ˴ϴÙ.

ÀÌ ½ÃÀåÀº À¯ÀüÀÚ Ä¡·á ¹× ¹é½ÅÀ» °³¹ßÇÏ´Â Á¦¾à ȸ»ç¿¡¼­ºÎÅÍ ±âÃÊÀûÀÎ À¯ÀüÀÚ ¿¬±¸¸¦ ¼öÇàÇÏ´Â Çмú ¿¬±¸ ±â°ü¿¡ À̸£±â±îÁö ´Ù¾çÇÑ ÃÖÁ¾ »ç¿ëÀÚ¿¡°Ô ¼­ºñ½º¸¦ Á¦°øÇÕ´Ï´Ù. ÁÖ¿ä Á¦Á¶ °øÁ¤Àº °íü»ó ÇÕ¼º, PCR ÁõÆø, ¹ßÈ¿ ±â¹Ý »ý»ê ½Ã½ºÅÛ µîÀ¸·Î È®Àå °¡´ÉÇÏ°í ºñ¿ë È¿À²ÀûÀÎ DNA »ý»êÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÌ ¾÷°è¿¡¼­´Â ÀÚµ¿È­, ǰÁú °ü¸® ½Ã½ºÅÛ ¹× Á¤Á¦ ¹æ¹ý¿¡ À־ »ó´çÇÑ ±â¼ú Çõ½ÅÀ» º¼ ¼ö ÀÖ¾î »ý»ê È¿À²°ú Á¦Ç° ǰÁúÀÌ ¸ðµÎ Çâ»óµÇ¾ú½À´Ï´Ù. ¼¼°èÀûÀÎ ÃÊÁ¡ÀÌ Á¤¹ÐÀÇ·á, CRISPR-Cas9¿Í °°Àº À¯ÀüÀÚ ÆíÁý ±â¼ú, Â÷¼¼´ë Ä¡·áÁ¦·Î À̵¿ÇÏ´Â °¡¿îµ¥, DNA Á¦Á¶ ½ÃÀåÀº Á¾¾çÇÐ, Èñ±ÍÁúȯ, °¨¿°ÁõÀ» Æ÷ÇÔÇÑ ¿©·¯ Ä¡·á ºÐ¾ß¿¡ °ÉÃÄ ±× ¹ßÀÚÃ븦 °è¼Ó È®´ëÇØ Çö´ë »ý¸í°øÇÐÀÇ Áøº¸¿¡ ÇʼöÀûÀÎ ±âµÕÀ¸·Î¼­ÀÇ ÁöÀ§¸¦ È®¸³Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼¼°èÀÇ DNA Á¦Á¶ ½ÃÀåÀº »ý¸í°øÇÐÀÇ Àü¸ÁÀ» ±Ùº»ÀûÀ¸·Î ¹Ù²Ù°í Àü·Ê ¾ø´Â ¼ºÀå ±âȸ¸¦ âÃâÇÏ´Â ¸î °¡Áö °­·ÂÇÑ ÃËÁø¿äÀο¡ ÀÇÇØ Áö¿øµÇ°í ÀÖ½À´Ï´Ù. ±× ù ¹øÂ° ¿äÀÎÀº À¯ÀüÀÚ Ä¡·á °³¹ßÀÇ ±Þ°ÝÇÑ ¼ºÀåÀ̸ç, ¼ö¸¹Àº ÀÓ»ó½ÃÇèÀÌ ±ÔÁ¦ ´ç±¹ÀÇ ÆÄÀÌÇÁ¶óÀÎÀ» Åë°úÇϰí USFDA ¹× EMA µîÀÇ ±â°üÀ¸·ÎºÎÅÍ ½ÂÀÎÀ» ¹Þ¾Æ °íǰÁúÀÇ Ä¡·á¿ë DNA Á¦Ç°¿¡ ´ëÇÑ Å« ¼ö¿ä°¡ ź»ýÇϰí ÀÖ½À´Ï´Ù. COVID-19 ÆÒµ¥¹ÍÀº ½Å¼ÓÇÑ ¹é½Å °³¹ß°ú »ý»ê ´É·Â, ƯÈ÷ »ý»ê¿¡ ÷´Ü DNA ÅÛÇø´°ú Çö󽺹̵带 ÇÊ¿ä·Î ÇÏ´Â mRNA ¹é½ÅÀÇ Á߿伺À» ºÎ°¢½ÃÄÑ ½ÃÀå ¼ºÀåÀ» ÇöÀúÇÏ°Ô °¡¼ÓÈ­Çß½À´Ï´Ù. ÇÕ¼º »ý¹°ÇÐ ¹× À¯Àü °øÇÐ ¿¬±¸¿¡ ´ëÇÑ ¹Î°£ ¹× °ø°ø ºÎ¹® ÅõÀÚ Áõ°¡´Â ¸ÂÃãÇü DNA ÇÕ¼º ¼­ºñ½º¿Í Ç¥ÁØÈ­µÈ DNA ±¸¼º¿ä¼Ò¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÃÀåÀº ±¤¹üÀ§ÇÑ ¹®¼­È­, ǰÁú °ü¸® Á¶Ä¡, ÀûÀýÇÑ Á¦Á¶ ±âÁØ(GMP) Áؼö¸¦ ¿ä±¸ÇÏ´Â ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¸¦ Æ÷ÇÔÇÑ ÇöÀúÇÑ ¾ïÁ¦¿äÀο¡ Á÷¸éÇϰí ÀÖÀ¸¸ç, ÀÌ´Â »ý»ê ºñ¿ë°ú ½ÃÀå Ãâ½Ã±îÁöÀÇ ½Ã°£À» Å©°Ô Áõ°¡½Ãŵ´Ï´Ù. ÃÖ÷´Ü Á¦Á¶ ½Ã¼³À» ¼³¸³ÇÏ´Â µ¥ ÇÊ¿äÇÑ °í¾×ÀÇ ¼³ºñ ÅõÀÚ¿Í Àü¹®ÀûÀÎ ¼÷·Ã Àη°ú °í±Þ ÀåºñÀÇ Çʿ伺ÀÌ ½Å±Ô ½ÃÀå ÁøÀÔÀÇ À庮ÀÌ µÇ°í ÀÖ½À´Ï´Ù. DNA ¾ÈÁ¤¼º À¯Áö, ¼øµµ ¼öÁØ È®º¸, ½ÇÇè½Ç ±Ô¸ð¿¡¼­ »ó¾÷ ±Ô¸ð·ÎÀÇ »ý»ê °øÁ¤ È®Àå¿¡ °üÇÑ ±â¼úÀû °úÁ¦´Â ¿©ÀüÈ÷ °æ¿µ»óÀÇ Á¦¾àÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸Çϰí, DNA µ¥ÀÌÅÍ º¸Á¸, ³ó¾÷ »ý¸í°øÇÐ, ȯ°æ º¹±¸ µî ½ÅÈï ºÐ¾ß¿¡¼­ÀÇ DNA ÀÀ¿ëÀÇ È®´ë°¡ ÀÌ ½ÃÀå¿¡ Å« ºñÁî´Ï½º ±âȸ¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. °³ÀÎÈ­µÈ ÀÇ·á Á¢±Ù¹ýÀÇ Ã¤Åà Ȯ´ë´Â ȯÀÚ Æ¯ÀÌÀû DNA ±¸Á¶¿Í ¸ÂÃãÇü Á¦Á¶ ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ ¾ß±âÇϰí ÀÖ½À´Ï´Ù. ÀÚµ¿È­, ÀΰøÁö´É ÁÖµµÀÇ Ç°Áú°ü¸®, ½Å±Ô ÇÕ¼º¹ý µîÀÇ ±â¼úÀû Áøº¸·Î ºñ¿ë Àý°¨°ú È¿À² Çâ»óÀ» À§ÇÑ »õ·Î¿î ±æÀÌ ¿­¸®°í ÀÖ´Â ÇÑÆí, ¼¼°èÀûÀÎ À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡·Î DNA ±â¹Ý Ä¡·á ¼Ö·ç¼ÇÀÇ ´ëÀÀ°¡´É ½ÃÀåÀº °è¼Ó È®´ëµÇ°í ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ DNA Á¦Á¶ ½ÃÀå, DNA À¯Çüº°, 2020-2032³â

Á¦5Àå ¼¼°èÀÇ DNA Á¦Á¶ ½ÃÀå, ¿ëµµº°, 2020-2032³â

Á¦6Àå ¼¼°èÀÇ DNA Á¦Á¶ ½ÃÀå, ±â¼úº°, 2020-2032³â

Á¦7Àå ¼¼°èÀÇ DNA Á¦Á¶ ½ÃÀå, µî±Þº°, 2020-2032³â

Á¦8Àå ¼¼°èÀÇ DNA Á¦Á¶ ½ÃÀå, »ý»ê ½ºÄÉÀϺ°, 2020-2032³â

Á¦9Àå ¼¼°èÀÇ DNA Á¦Á¶ ½ÃÀå, ÃÖÁ¾ »ç¿ëÀÚº°, 2020-2032³â

Á¦10Àå ¼¼°èÀÇ DNA Á¦Á¶ ½ÃÀå, Áö¿ªº°, 2020-2032³â

Á¦11Àå °æÀï ±¸µµ

Á¦12Àå ºÐ¼®°¡ Ãßõ

Á¦13Àå Âü°í¹®Çå°ú Á¶»ç¹æ¹ý

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

DNA Manufacturing Market is estimated to be valued at USD 6.44 Bn in 2025 and is expected to reach USD 19.56 Bn by 2032, growing at a compound annual growth rate (CAGR) of 17.2% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 6.44 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 17.20% 2032 Value Projection: USD 19.56 Bn

The global DNA manufacturing market represents a rapidly evolving sector within the biotechnology industry, encompassing the production, synthesis, and commercial manufacturing of deoxyribonucleic acid (DNA) for various applications across pharmaceutical, research, diagnostic, and therapeutic domains. This market has emerged as a critical component of the modern bioeconomy, driven by unprecedented advances in genetic engineering, synthetic biology, and personalized medicine. DNA manufacturing involves sophisticated processes including chemical synthesis, enzymatic production, and bio-manufacturing techniques to create high-quality DNA constructs, plasmids, oligonucleotides, and synthetic genes.

The market serves diverse end users ranging from pharmaceutical companies developing gene therapies and vaccines to academic research institutions conducting fundamental genetic research. Key manufacturing processes include solid-phase synthesis, PCR amplification, and fermentation-based production systems that enable scalable and cost-effective DNA production. The industry has witnessed significant technological breakthroughs in automation, quality control systems, and purification methodologies, enhancing both production efficiency and product quality. As the global focus shifts toward precision medicine, gene editing technologies like CRISPR-Cas9, and next-generation therapeutics, the DNA manufacturing market continues to expand its footprint across multiple therapeutic areas including oncology, rare diseases, and infectious diseases, establishing itself as an indispensable pillar of modern biotechnological advancement.

Market Dynamics

The global DNA manufacturing market is propelled by several robust drivers that are fundamentally reshaping the biotechnology landscape and creating unprecedented growth opportunities. The primary driver stems from the exponential growth in gene therapy development, with numerous clinical trials advancing through regulatory pipelines and receiving approvals from agencies like the USFDA and EMA, creating substantial demand for high-quality therapeutic DNA products. The COVID-19 pandemic significantly accelerated market growth by highlighting the critical importance of rapid vaccine development and manufacturing capabilities, particularly for mRNA vaccines that require sophisticated DNA templates and plasmids for production. Rising investments in synthetic biology and genetic engineering research by both private and public sectors are driving demand for custom DNA synthesis services and standardized DNA components. However, the market faces notable restraints including stringent regulatory frameworks that require extensive documentation, quality control measures, and compliance with Good Manufacturing Practice (GMP) standards, which significantly increase production costs and time-to-market. The high capital investment required for establishing state-of-the-art manufacturing facilities, coupled with the need for specialized skilled personnel and advanced equipment, creates barriers for new market entrants. Technical challenges related to maintaining DNA stability, ensuring purity levels, and scaling production processes from laboratory to commercial scale continue to pose operational constraints. Nevertheless, the market presents substantial opportunities driven by the expanding applications of DNA in emerging fields such as DNA data storage, agricultural biotechnology, and environmental remediation. The growing adoption of personalized medicine approaches is creating demand for patient-specific DNA constructs and custom manufacturing services. Technological advancements in automation, artificial intelligence-driven quality control, and novel synthesis methods are opening new avenues for cost reduction and efficiency improvements, while the increasing prevalence of genetic disorders globally continues to expand the addressable market for DNA-based therapeutic solutions.

Key Features of the Study

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global DNA Manufacturing Market, By Type of DNA, 2020-2032, (USD Bn)

5. Global DNA Manufacturing Market, By Application, 2020-2032, (USD Bn)

6. Global DNA Manufacturing Market, By Technology, 2020-2032, (USD Bn)

7. Global DNA Manufacturing Market, By Grade, 2020-2032, (USD Bn)

8. Global DNA Manufacturing Market, By Production Scale, 2020-2032, (USD Bn)

9. Global DNA Manufacturing Market, By End User, 2020-2032, (USD Bn)

10. Global DNA Manufacturing Market, By Region, 2020 - 2032, Value (USD Bn)

11. Competitive Landscape

12. Analyst Recommendations

13. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â